For the Inventor, By the Inventor

Enter assignee name

San Diego, CA, United States of America

Vical Incorporated

USPTO Granted Patents = 64

% Expired Patents = 53.1

EPO Patents = 9

Trademarks = 1

Forward Citations = 5,438

Loading Chart...

Loading Chart...

49 inventors (with patents filed for the assignee):

Adrian Vilalta (18 out of 18 patents)

Michal Margalith (14 out of 14 patents)

Lichun Dong (13 out of 13 patents)

4. David Martin Koelle (13 out of 33 patents)

5. Andrew John Geall (12 out of 101 patents)

6. Philip L Felgner (11 out of 49 patents)

7. Carl J Wheeler (10 out of 10 patents)

8. Mary Kopke Wloch (9 out of 9 patents)

9. Jon Asher Wolff (7 out of 97 patents)

10. Dennis A Carson (6 out of 88 patents)

11. Gary H Rhodes (6 out of 9 patents)

12. Robert Wallace Malone (6 out of 16 patents)

13. Gary G Hermanson (5 out of 7 patents)

14. Catherine J Luke (5 out of 7 patents)

15. Thomas G Evans (5 out of 5 patents)

Core Competencies:

Polynucleotide Vaccines

HSV-2

Human Cytomegalovirus

Immune Response Enhancement

Influenza Vaccine

Cationic Lipids

Gene Therapy

Cancer Treatment

Adjuvants

Plasmids

Lipid-mediated Delivery

Sterile Medicaments

64 patents: Sort by Forward Citations

1. 9205146 - Compositions and methods for vaccinating against HSV-2 (2015-12-08),

2. 9180162 - Codon-optimized polynucleotide-based vaccines against human cytomegalovirus infection (2015-11-10),

3. 9161973 - Compositions and methods for vaccinating against HSV-2 (2015-10-20),

4. 9102950 - Compositions and methods for enhancing immune responses to vaccines (2015-08-11),

5. 8999345 - Compositions and methods for enhancing immune responses to vaccines (2015-04-07),

6. 8852611 - Compositions and methods for vaccinating against HSV-2 (2014-10-07),

7. 8852610 - Compositions and methods for vaccinating against HSV-2 (2014-10-07),

8. 8840904 - Compositions and methods for vaccinating against HSV-2 (2014-09-23),

9. 8840903 - Compositions and methods for vaccinating against HSV-2 (2014-09-23),

10. 8834894 - Compositions and methods for vaccinating against HSV-2 (2014-09-16),

11. 8828408 - Compositions and methods for vaccinating against HSV-2 (2014-09-09),

12. 8821890 - Influenza virus vaccine composition and methods of use (2014-09-02),

13. 8673317 - [object Object] (2014-03-18),

14. 8541628 - Complex cationic lipids having quaternary nitrogens therein (2013-09-24),

15. 8435557 - Method for producing sterile polynucleotide based medicaments (2013-05-07),

Company Overview

Vical Incorporated, based in San Diego, CA, specializes in the development of innovative polynucleotide vaccines aimed at enhancing immune responses against various infectious diseases and cancers. The company focuses on advanced technologies such as gene therapy and the use of cationic lipids to improve vaccine efficacy. Its research encompasses critical areas including vaccines for herpes simplex virus type 2 (HSV-2), human cytomegalovirus, and influenza, positioning Vical at the forefront of vaccine and therapeutic advancements.

Profile summary synthesized from public USPTO records and patent filings.

Company Badge

USPTO Data Jan 1 1976 - Oct 13 2026

64 Patents

#97 in San Diego, CA

#1,319 in California

#5,682 in US

#11,476 in the World

San Diego, CA, United States of America

Vical Incorporated

Forward Citations = 5,438

49 inventors:

Adrian Vilalta (18 out of 18 patents)

Michal Margalith (14 out of 14 patents)

Lichun Dong (13 out of 13 patents)

4. David Martin Koelle (13 out of 33 patents)

5. Andrew John Geall (12 out of 101 patents)

IDiyas Innovation Intelligence. (2026). Company Patent Portfolio: Vical Incorporated. Retrieved from https://idiyas.com/company/vical

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]

Loading…